Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eton Pharmaceuticals Inc.

https://etonpharma.com

Latest From Eton Pharmaceuticals Inc.

Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea

Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Eton Pharmaceuticals Inc.
  • Senior Management
  • Sean Brynjelsen, CEO
    Wilson Troutman, CFO
    Bharathi Devarakonda, SVP, Regulatory Affairs & Product Dev.
    Scott Grossenback, VP, Sales & Mktg.
    David Krempa, Exec. Dir., Bus. Dev.
  • Contact Info
  • Eton Pharmaceuticals Inc.
    Phone: (847) 787-7361
    21925 W Field Pkwy. #235
    Deer Park, IL 60010
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register